Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.36 |
| ▸ | CHRNG | P07510 | 1/20 | 0.36 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CHRND | Q07001 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599387 | 0.89 | ALOX5 (0.42) | HDAC3HDAC1HDAC2HDAC6ALOX5 | |
| SCHEMBL12077298 | 0.88 | HDAC3 (0.39) | HDAC3HDAC1HDAC2HDAC6ALOX5 | |
| Methyl Alcohol SCHEMBL15609328 | 0.85 | CHRNA1 (0.39) | HDAC3HDAC1HDAC2HDAC6ALOX5 | |
| SCHEMBL23231962 | 0.84 | CA12 (0.39) | HDAC3HDAC1HDAC2HDAC6ALOX5 | |
| SCHEMBL12078176 | 0.80 | CA12 (0.36) | HDAC3HDAC1HDAC2HDAC6HRH3 | |
| SCHEMBL12077778 | 0.80 | HDAC3 (0.39) | HDAC3HDAC1HDAC2HDAC6HRH3 | |
| SCHEMBL15420336 | 0.79 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC6ALOX5 | |
| SCHEMBL12078222 | 0.78 | CHRNA1 (0.41) | HDAC3HDAC1HDAC2HDAC6CHRNA1 | |
| SCHEMBL9367762 | 0.78 | ALOX5 (0.41) | ALOX5OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL18259559 | 0.77 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC6ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861585-B1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-9802918-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802918-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802918-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-9540347-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540347-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-9540347-B2 | Pyridineamine compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-5276037-A | Antiinflammatory agents, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-04 | — | — | US | disclosed |
| US-5272173-A | 5-lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| US-5260442-A | Process for the manufacture of crystalline quinolinium salts and their oxidation to 1-alkyl-2-quinolones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-09 | — | — | US | disclosed |
| US-5240941-A | Enzyme inhibitors; antiinflammatory agents, antiallergens | ICI PHARMA (FR) | 1993-08-31 | — | — | US | disclosed |
| US-5225438-A | Lipoxygenase inhibitors for antiinflammatory agents or antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-07-06 | — | — | US | disclosed |
| US-5217969-A | Antiinflammatory, antiulcer agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| EP-0488602-A1 | Aryl derivatives | ZENECA LIMITED (GB) | 1992-06-03 | — | — | EP | disclosed |
| EP-0485111-A2 | The use of lipoxygenase and cyclooxygenase inhibitors as synergistic agents | ZENECA LIMITED (GB) | 1992-05-13 | — | — | EP | disclosed |
| EP-0466452-A2 | Thioxo heterocycles and their pharmaceutical use | ZENECA LIMITED (GB) | 1992-01-15 | — | — | EP | disclosed |
| EP-0462813-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158670-A1 | PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | HDAC3 1783/4885HDAC1 1189/4885HDAC2 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.